DSpace Fukushima Medical University

福島県立医科大学学術成果リポジトリ = Fukushima Medical University Repository >
福島医学会 = The Fukushima Society of Medical Science >
Fukushima Journal of Medical Science >
Vol.64 (2018) >

このアイテムの引用には次の識別子を使用してください: http://ir.fmu.ac.jp/dspace/handle/123456789/693


ファイル 記述 サイズフォーマット
FksmJMedSci_64_p46.pdf1.36 MBAdobe PDFダウンロード
タイトル: Immunotherapy for esophageal squamous cell carcinoma: a review
著者: Mimura, Kosaku
Yamada, Leo
Ujiie, Daisuke
Hayase, Suguru
Tada, Takeshi
Hanayama, Hiroyuki
Aung Kyi Thar Min
Shibata, Masahiko
Momma, Tomoyuki
Saze, Zenichiro
Ohki, Shinji
Kono, Koji
学内所属: 消化管外科学講座
誌名/書名: Fukushima Journal of Medical Science
巻: 64
号: 2
開始ページ: 46
終了ページ: 53
発行日: 2018年
抄録: Cancer vaccines and immune checkpoint inhibitors (ICI) have recently been employed as immunotherapies for esophageal squamous cell carcinoma (ESCC). Cancer vaccines for ESCC have yielded several promising results from investigator-initiated phase I and II clinical trials. Furthermore, a Randomized Controlled Trial as an adjuvant setting after curative surgery is in progress in Japan. On the other hand, ICI, anti-CTLA-4 mAb and anti-PD-1 mAb, have demonstrated tumor shrinkage and improved overall survival in patients with multiple cancer types. For ESCC, several clinical trials using anti-PD-1/anti-PD-L1 mAb are underway with several recent promising results. In this review, cancer vaccines and ICI are discussed as novel therapeutic strategies for ESCC.
出版者: The Fukushima Society of Medical Science
出版者(異表記): 福島医学会
本文の言語: eng
このページのURI: http://ir.fmu.ac.jp/dspace/handle/123456789/693
本文URL: https://ir.fmu.ac.jp/dspace/bitstream/123456789/693/1/FksmJMedSci_64_p46.pdf
ISSN: 0016-2590
DOI: 10.5387/fms.2018-09
PubMed番号: 30058598
関連ページ: https://doi.org/10.5387/fms.2018-09
権利情報: © 2018 The Fukushima Society of Medical Science
出現コレクション:Vol.64 (2018)


ファイル 記述 サイズフォーマット
FksmJMedSci_64_p46.pdf1.36 MBAdobe PDFダウンロード



DSpace Software Copyright © 2002-2006 MIT and Hewlett-Packard